The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment

被引：40
|
作者：
Holubec, Lubos [1 ,4 ]
Polivka, Jiri, Jr. [1 ,2 ]
Safanda, Martin [4 ]
Karas, Michal [3 ]
Liska, Vaclav [1 ]
机构：
[1] Charles Univ Prague, Biomed Ctr, Fac Med Plzen, Plzen, Czech Republic
[2] Charles Univ Prague, Dept Histol & Embryol, Fac Med Plzen, Plzen, Czech Republic
[3] Charles Univ Prague, Dept Hematol & Oncol, Fac Med Plzen, Plzen, Czech Republic
[4] Na Homolce Hosp, Dept Clin Oncol, Prague, Czech Republic
来源：
ANTICANCER RESEARCH | 2016年 / 36卷 / 09期
关键词：
Colorectal cancer; cetuximab; immune response; targeted therapy; immunomodulation; review; GAMMA RECEPTOR POLYMORPHISMS; CHECKPOINT INHIBITORS; MONOCLONAL-ANTIBODIES; THERAPY; EGFR; IMMUNOTHERAPY; PANITUMUMAB; SURVIVAL; MICROENVIRONMENT; CYTOTOXICITY;
D O I：
10.21873/anticanres.10985
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, are widely used targeted therapeutics for the treatment of patients with colorectal cancer. The clinical significance of these drugs has so far been associated with combined chemotherapy or radiation. It has been shown that these treatment strategies have their clinical limitations and do not fully exploit the immunomodulatory effect of these drugs. In this review, we discuss the mechanisms of immunomodulation together with the anticancer immune response to the monoclonal antibodies targeted to the EGFR. The combination of anti-EGFR monoclonal antibodies with other immunotherapeutic treatment modalities certainly brings new opportunities for targeted therapy in patients with colorectal cancer.
引用
收藏
页码：4421 / 4426
页数：6
相关论文
共 50 条
  • [31] Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
    Pietrantonio, Filippo
    Petrelli, Fausto
    Coinu, Andrea
    Di Bartolomeo, Maria
    Borgonovo, Karen
    Maggi, Claudia
    Cabiddu, Mary
    Iacovelli, Roberto
    Bossi, Ilaria
    Lonati, Veronica
    Ghilardi, Mara
    de Braud, Filippo
    Barni, Sandro
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (05) : 587 - 594
  • [32] Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab
    Jacome, Alexandre A.
    Eng, Cathy
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (12) : 1247 - 1263
  • [33] Assessment of exposure-response relationship for cetuximab in patients with metastatic colorectal cancer and head and neck cancer
    Pena-Cabia, Silvia
    Royuela-Vicente, Ana
    Ramos-Diaz, Ruth
    Gutierrez-Nicolas, Fernando
    Garcia-Diaz, Benito
    Lopez-Martin, Ana
    FARMACIA HOSPITALARIA, 2022, 46 (01) : 21 - 26
  • [34] Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients
    Vincenzi, B.
    Galluzzo, S.
    Santini, D.
    Rocci, L.
    Loupakis, F.
    Correale, P.
    Addeo, R.
    Zoccoli, A.
    Napolitano, A.
    Graziano, F.
    Ruzzo, A.
    Falcone, A.
    Francini, G.
    Dicuonzo, G.
    Tonini, G.
    ANNALS OF ONCOLOGY, 2011, 22 (05) : 1141 - 1146
  • [35] Cetuximab therapy in the treatment of metastatic colorectal cancer: The future frontier?
    Gomez, D.
    De Rosa, A.
    Addison, A.
    Brooks, A.
    Malik, H. Z.
    Cameron, I. C.
    INTERNATIONAL JOURNAL OF SURGERY, 2013, 11 (07) : 507 - 513
  • [36] Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer
    Hoyle, Martin
    Peters, Jaime
    Crathorne, Louise
    Jones-Hughes, Tracey
    Cooper, Chris
    Napier, Mark
    Hyde, Chris
    VALUE IN HEALTH, 2013, 16 (02) : 288 - 296
  • [37] Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer
    Feng Wen
    Qiu Li
    World Journal of Gastroenterology, 2016, (23) : 5332 - 5341
  • [38] Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer
    Jones, Vivian Truong
    Graves-Deal, Ramona
    Cao, Zheng
    Bogatcheva, Galina
    Ramirez, Marisol A.
    Harmych, Sarah J.
    Higginbotham, James N.
    Sharma, Vineeta
    Damalanka, Vishnu C.
    Wahoski, Claudia C.
    Joshi, Neeraj
    Irudayam, Maria Johnson
    Roland, Joseph T.
    Ayers, Gregory D.
    Liu, Qi
    Coffey, Robert J.
    Janetka, James W.
    Singh, Bhuminder
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2024, 81 (01)
  • [39] EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
    Chiadini, Elisa
    Scarpi, Emanuela
    Passardi, Alessandro
    Calistri, Daniele
    Valgiusti, Martina
    Saragoni, Luca
    Zoli, Wainer
    Amadori, Dino
    Ulivi, Paola
    ONCOLOGY LETTERS, 2015, 9 (03) : 1432 - 1438
  • [40] Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: A meta-analysis
    Shen, Yue
    Yang, Jian
    Xu, Zhi
    Gu, Dong-Ying
    Chen, Jin-Fei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (21) : 2712 - 2718
12345